Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Mary Bridge Children's Hospital and Health Center
mi
from
Tacoma, WA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Mary Bridge Children's Hospital and Health Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Saint Vincent Hospital
mi
from
Green Bay, WI
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Miller Children's and Women's Hospital Long Beach
mi
from
Long Beach, CA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Miller Children's and Women's Hospital Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
MedStar Georgetown University Hospital
mi
from
Washington,
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
MedStar Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
mi
from
Hollywood, FL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
mi
from
Hollywood, FL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Nemours Children's Clinic - Jacksonville
mi
from
Jacksonville, FL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Nemours Children's Clinic - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Nicklaus Children's Hospital
mi
from
Miami, FL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Nicklaus Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
All Children's Hospital
mi
from
Saint Petersburg, FL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Saint Joseph's Hospital/Children's Hospital-Tampa
mi
from
Tampa, FL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Saint Joseph's Hospital/Children's Hospital-Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Kansas Cancer Center
mi
from
Kansas City, KA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Kansas Cancer Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Michigan State University Clinical Center
mi
from
East Lansing, MI
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Michigan State University Clinical Center
mi
from
East Lansing, MI
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
The Mayo Clinic
mi
from
Rochester, MN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Morristown Medical Center
mi
from
Morristown, NJ
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Morristown Medical Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
New York Medical College
mi
from
Valhalla, NY
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Dayton Children's Hospital
mi
from
Dayton, OH
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Dayton Children's Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Greenville Cancer Treatment Center
mi
from
Greenville, SC
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Greenville Cancer Treatment Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Marshfield Clinic
mi
from
Marshfield, WI
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Royal Brisbane and Women's Hospital
mi
from
Herston,
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Royal Brisbane and Women's Hospital
mi
from
Herston,
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Augusta Oncology Associates
mi
from
Augusta, GA
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Augusta Oncology Associates
mi
from
Augusta, GA
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Central Georgia Cancer Care
mi
from
Macon, GA
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Central Georgia Cancer Care
mi
from
Macon, GA
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Missouri Cancer Associates
mi
from
Columbia, MO
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Missouri Cancer Associates
mi
from
Columbia, MO
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
The West Clinic, PC
mi
from
Memphis, TN
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
University of Miami
mi
from
Miami, FL
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Hematology-Oncology Centers of the Northern Rockies PC
mi
from
Billings, MT
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Hematology-Oncology Centers of the Northern Rockies PC
mi
from
Billings, MT
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
New York Oncology Hematology PC
mi
from
Albany, NY
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Weill Cornell Medical Center
mi
from
New York, NY
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated:  4/8/2016
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Enrolling
Updated: 4/8/2016
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials